Lee Ainslie Immuno Gen, Inc. Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $315,362 - $758,034	-25,310 Reduced 1.0%	2,493,217 $73.9 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $17.9 Million - $25.2 Million	-1,268,371 Reduced 33.49%	2,518,527 $40 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $15.3 Million - $81.6 Million	-4,069,511 Reduced 51.8%	3,786,898 $71.5 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $3.59 Million - $4.81 Million	977,466 Added 14.21%	7,856,409 $30.2 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $15.1 Million - $21 Million	3,325,815 Added 93.6%	6,878,943 $34.1 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $3.52 Million - $5.09 Million	786,654 Added 28.44%	3,553,128 $17 Million
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $8.71 Million - $15.9 Million	2,766,474 New	2,766,474 $12.4 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.